Co je nového v srdečním selhání se zachovalou ejekční frakcí levé komory za posledních pět let?
[What is new in heart failure with preserved ejection fraction within last five years?]
Jazyk čeština Země Česko Médium print
Typ dokumentu časopisecké články, přehledy
PubMed
25130634
PII: 49406
- MeSH
- biologické markery MeSH
- echokardiografie MeSH
- funkce levé komory srdeční * MeSH
- lidé MeSH
- prognóza MeSH
- progrese nemoci MeSH
- srdeční selhání diagnostické zobrazování patofyziologie MeSH
- tepový objem MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- biologické markery MeSH
Heart failure with preserved ejection fraction of left ventricle (heart failure with normal ejection fraction, HFPEF, HFNEF) is frequent disease with serious consequences. Incidence of HFPEF in population is still growing. The exact pathophysiological mechanism of HFPEF remain unclear .Recent evidence suggests a relationship between inflammation associated with obesity or Diabetes mellitus and progression of HFPEF. Consistently, it has been reported that serum concentration of some pro-inflammatory markers such as adiponectin is positively related to HFPEF. By HFPEF is attended diastolic dysfunction. Diastolic dysfunction is linked to many other cardiac and non-cardiac diseases. Despite the great effort and new therapeutic approaches the prognosis of HFPEF does not improve. The gold standard in HFPEF diagnosis remains heart catheterization. Electrocardiography, chest X-ray, blood examination including diagnostic markers of heart failure and mainly echocardiography with Doppler imaging are used diagnose the underlying disease leading to heart failure.
